Two biotechs, SIGA and PharmAthene, vying to establish a foothold in the potentially vast biodefense market are in the midst of duking it out in a multibillion dollar legal battle. The crux of the dispute is a smallpox vaccine …
Shares of drugmaker InterMune have more than doubled in premarket trading after a European advisory panel backed the company’s experimental lung treatment Esbriet (pirfenidone), something the biotech failed to accomplish in the…
Shares of drugmaker InterMune have more than doubled in premarket trading after a European advisory panel backed the company’s experimental lung treatment Esbriet (pirfenidone), something the biotech failed to accomplish in the…
The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company — facing a severe patent cliff — has high hopes for. If approved, it could be a multibillion-dollar…
More than a year after AstraZeneca filed for approval, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome — but approval isn’t a su…